二甲双胍对局限期前列腺癌根治性治疗后的生化失败保护作用
本研究评估二甲双胍对接受根治性前列腺切除术或放疗的局限期前列腺癌患者生化失败的影响。1449例患者中148例(10.2%)使用二甲双胍,多因素分析显示二甲双胍与5年及总体生化失败风险显著降低相关,Cox回归中独立关联40%相对风险降低,但单因素分析未见差异。
要点
- 多因素分析中二甲双胍使用与总体及5年生化失败风险显著降低相关。
- Cox回归显示二甲双胍独立关联40%生化失败相对风险降低。
- 单因素分析中1、3、5年生化失败率无显著差异。
核心结论
- 多因素分析中二甲双胍使用与根治性治疗后的总体及5年生化失败风险显著降低相关,但单因素分析未观察到该趋势。
研究设计与样本
- 回顾性评估2007年7月至2020年1月间1449例接受根治性前列腺切除术(n=1338,92.3%)或放疗(n=108,7.5%)的局限期前列腺癌患者,分析二甲双胍使用与生化结局。
主要发现
- 148例(10.2%)在诊断时使用二甲双胍,使用者年龄更大、BMI更高且Gleason评分>7比例更高。
- 平均随访3.6±2.6年,多因素分析显示二甲双胍使用者在5年及总体生化失败风险显著更低,Cox回归中独立关联40%相对风险降低。
- 单因素分析中1、3、5年生化失败率无显著差异。
关键数值与推荐
- 生化失败率评估总体及1、3、5年;生化失败时间用Kaplan-Meier估计,多因素采用logistic回归和Cox比例风险模型校正显著差异。
- 雄激素剥夺治疗依据NCCN指南使用。
临床怎么用
- 对于合并糖尿病的局限期前列腺癌患者,二甲双胍使用可能与更好的生化结局相关,但需前瞻性研究验证。
局限性
- 回顾性设计,二甲双胍组样本量较小(148例)且疾病更侵袭,单因素与多因素结果不一致,需未来研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the impact of metformin on biochemical failure (BF) in localized prostate cancers (PC) treated with radical prostatectomy or radiation therapy. MATERIALS AND METHODS: About 1449 patients undergoing radical prostatectomy (n = 1338, 92.3%) or radiation therapy (n = 108, 7.5%) for localized PC between July 2007 and January 2020 were evaluated for metformin use, demographic/oncologic characteristics, and biochemical outcomes. Androgen deprivation therapy was utilized per NCCN guidelines. BF rates were assessed overall and at 1, 3, and 5 years. Time to BF was estimated via Kaplan-Meier; logistic regression and Cox proportionate hazards models were generated to adjust for significant differences. RESULTS: Of 1449 patients, 148 (10.2%) utilized metformin at time of diagnosis, while 1,301 (89.8%) did not. Patients on metformin were significantly older, had higher body mass indexes, and more aggressive disease (Gleason score >7). At a mean ± SD follow-up of 3.6 ± 2.6 years, patients on metformin were less likely to experience BF at later timepoints; however, univariate analysis showed no differences at 1, 3, and 5 years. In multivariate analysis, patients on metformin were significantly less likely to experience BF at 5 years and overall in both treatment groups. In Cox regression, metformin was independently associated with a 40% relative risk reduction in BF. CONCLUSION: In multivariate analysis, metformin use was associated with a significant risk reduction in BF overall and at 5 years following primary treatment; this trend was not witnessed in univariate analysis. This suggests the need for future investigations of metformin's role in disease-free survival in men with localized PC.
引用
- Huynh LM, Keit E, Huang E, et al. Protective Effects of Metformin Against Biochemical Failure Following Radical Prostatectomy or Radiation Therapy in Localized Prostate Cancer. Urology. 2021. PMID: 33515557. doi:10.1016/j.urology.2021.01.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。